Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01989676
Title A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)
Recruitment Completed
Gender female
Phase Phase III
Variant Requirements No
Sponsors Pfizer

Her2-receptor positive breast cancer


Paclitaxel + Trastuzumab

Paclitaxel + Trazimera

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.